Literature DB >> 24595461

Quantitative evaluation of bone metastases from prostate cancer with simultaneous [18F] choline PET/MRI: combined SUV and ADC analysis.

Axel Wetter1, Christine Lipponer, Felix Nensa, Philipp Heusch, Herbert Rübben, Thomas W Schlosser, Thorsten D Pöppel, Thomas C Lauenstein, James Nagarajah.   

Abstract

OBJECTIVE: To quantitatively analyze bone metastases from prostate cancer and correlate the apparent diffusion coefficients (ADCs) and standardized uptake values (SUVs).
METHODS: Fifty-five patients with biopsy-proven prostate cancer or suspected recurrent prostate cancer were examined with simultaneous [18F] choline Positron emission tomography (PET)/MRI at 3 T. In 11 patients, thirty-two PET-positive bone lesions could be identified that were located in the field-of-view of the Diffusion weighted imaging-sequence. Region-of-interest and volume-of-interest analyses were performed to measure the mean and minimal ADCs and to assess maximum and mean SUVs of every bone lesion. Correlations between maximum and mean SUVs and mean and minimal ADCs were calculated.
RESULTS: The SUVmax of all lesions was 5.5±3.1 (mean±SD). The SUVmean was 1.8±0.9. The mean ADC (ADCmean) of all lesions was 0.67±0.13×10(-3) mm2/s. The minimal ADC (ADCmin) of all lesions was 0.56±0.14×10(-3) mm2/s. There was a moderate but significant inverse correlation of SUVmax vs. ADCmean with a correlation coefficient of -0.4 (p=0.02). There was also a significant inverse correlation of SUVmax vs. ADCmin with r=-0.41 (p=0.02).
CONCLUSION: Our initial results demonstrate a moderate but significant inverse correlation between increased choline metabolism and ADC values of bone metastases from prostate cancer. Further research on a multimodality approach using simultaneous PET/MRI in bone metastasis of prostate cancer seems to be justified.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24595461     DOI: 10.1007/s12149-014-0825-x

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  13 in total

Review 1.  Positron Emission Tomography (PET) in Oncology.

Authors:  Andrea Gallamini; Colette Zwarthoed; Anna Borra
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

2.  Prospective head-to-head comparison of 11C-choline-PET/MR and 11C-choline-PET/CT for restaging of biochemical recurrent prostate cancer.

Authors:  Matthias Eiber; Isabel Rauscher; Michael Souvatzoglou; Tobias Maurer; Markus Schwaiger; Konstantin Holzapfel; Ambros J Beer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-12       Impact factor: 9.236

Review 3.  Imaging and evaluation of patients with high-risk prostate cancer.

Authors:  Marc A Bjurlin; Andrew B Rosenkrantz; Luis S Beltran; Roy A Raad; Samir S Taneja
Journal:  Nat Rev Urol       Date:  2015-10-20       Impact factor: 14.432

4.  Usefulness of MRI-assisted metabolic volumetric parameters provided by simultaneous (18)F-fluorocholine PET/MRI for primary prostate cancer characterization.

Authors:  Yong-Il Kim; Gi Jeong Cheon; Jin Chul Paeng; Jeong Yeon Cho; Cheol Kwak; Keon Wook Kang; June-Key Chung; Euishin Edmund Kim; Dong Soo Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-11       Impact factor: 9.236

5.  Correlations between intravoxel incoherent motion diffusion-weighted MR imaging parameters and 18F-FDG PET/CT metabolic parameters in patients with vertebral bone metastases: initial experience.

Authors:  Sunghoon Park; Joon-Kee Yoon; Nam-Su Chung; Sang Hyun Kim; Jinwoo Hwang; Hyun Young Lee; Kyu-Sung Kwack
Journal:  Br J Radiol       Date:  2018-03-20       Impact factor: 3.039

6.  Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer.

Authors:  Barbara J Amorim; Vinay Prabhu; Sara S Marco; Debra Gervais; Willian E Palmer; Pedram Heidari; Mark Vangel; Philip J Saylor; Onofrio A Catalano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-06       Impact factor: 9.236

7.  Combined PET/MR: The Real Work Has Just Started. Summary Report of the Third International Workshop on PET/MR Imaging; February 17-21, 2014, Tübingen, Germany.

Authors:  D L Bailey; G Antoch; P Bartenstein; H Barthel; A J Beer; S Bisdas; D A Bluemke; R Boellaard; C D Claussen; C Franzius; M Hacker; H Hricak; C la Fougère; B Gückel; S G Nekolla; B J Pichler; S Purz; H H Quick; O Sabri; B Sattler; J Schäfer; H Schmidt; J van den Hoff; S Voss; W Weber; H F Wehrl; T Beyer
Journal:  Mol Imaging Biol       Date:  2015-06       Impact factor: 3.488

8.  The clinical role of multimodality imaging in the detection of prostate cancer recurrence after radical prostatectomy and radiation therapy: past, present, and future.

Authors:  Francesco Paparo; Michela Massollo; Ludovica Rollandi; Arnoldo Piccardo; Filippo Grillo Ruggieri; Gian Andrea Rollandi
Journal:  Ecancermedicalscience       Date:  2015-09-04

9.  Molecular research in urology 2014: update on PET/MR imaging of the prostate.

Authors:  Axel Wetter
Journal:  Int J Mol Sci       Date:  2014-07-31       Impact factor: 5.923

10.  Longitudinal analysis of bone metabolism using SPECT/CT and (99m)Tc-diphosphono-propanedicarboxylic acid: comparison of visual and quantitative analysis.

Authors:  Michael Beck; James C Sanders; Philipp Ritt; Julia Reinfelder; Torsten Kuwert
Journal:  EJNMMI Res       Date:  2016-07-28       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.